ProjectUpdated on 28 August 2025
Single Cell Drug Screening AI Platform
About
To investigate tumor heterogeneity, we have developed a single-cell culture device capable of isolating and individually culturing over 1.4 million single cells for high-throughput drug testing. Leveraging our proprietary AI model, we can accurately identify drug-resistant single cells, enabling further investigation and more precise prediction of treatment efficacy.
This platform accelerate cancer reserach, R&D progress for advanced therapeutics and predictive diagnostics for personalised cancer treatment.
Project Location
- China (Hong Kong)
Project Format
- Private Project
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Feasibility Study Completed
Main Project Sector
- Technology
Technology
- Bio-Tech
Total Project Value
- 2,500,001 to 5,000,000 USD
Investment Capital Required
- 1,000,001 to 2,500,000 USD
Interested Format of Cooperation
- Minority Shareholdings
- Public–private partnership / Concession
- R&D Cooperation
Preferred Financing Model
- Equity
- Open for negotiation
Previous Funding Stage
- None
Main Service(s) Required
- Professional Services
Attached files
Organisation
Provectus Therapeutics Limited
Hong Kong, China (Hong Kong)
Similar opportunities
Project
- No
- None
- Bio-Tech
- Technology
- Joint Venture
- R&D Cooperation
- Project Planning
- Health Technology
- Financial Services
- Open for Negotiation
- Open for negotiation
- Professional Services
- 1,000,001 to 2,500,000 USD
- 2,500,001 to 5,000,000 USD
- Public-Private Partnership Project
Daisy Tan
Business Development Manager at InnoHK Centre for Translational Stem Cell Biology
Hong Kong, China (Hong Kong)
Project
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
- Yes
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Private Project
- R&D Cooperation
- Seed & Pre-Series
- Financial Services
- Business Valuation
- Corporate Services
- Open for Negotiation
- Open for negotiation
- Professional Services
- Minority Shareholdings
- Institutional Investment
- Feasibility Study Completed
- Market Entry Strategic Analysis
- Private Equity & Venture Capital
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
Shanghai, China
Project
- No
- Bio-Tech
- Operations
- Technology
- IP Related
- Consultancy
- R&D Cooperation
- Risk Management
- Health Technology
- Seed & Pre-Series
- Medical Technology
- Financial Services
- Business Valuation
- Financial Advisory
- Open for Negotiation
- Open for negotiation
- Professional Services
- 5,000,001 to 7,500,000 USD
- 10,000,001 to 25,000,000 USD
- Private Equity & Venture Capital
- Public-Private Partnership Project
- Risk Management (Financial Services)
Jiang Liu
Research Assistant Professor at Oncoimmunostics Limited
Hong Kong, China (Hong Kong)